Investigating how MS4A7 affects tumor resistance to immunotherapy
Official title: MS4A7 in tumor resistance to immunotherapy
Funded at University of Michigan at Ann Arbor · NIH-11046677 · Data updated 2026-11-12
This study is looking at a protein called MS4A7 in immune cells that are found in tumors to see how it affects the success of cancer treatments, with the hope of finding new ways to make immunotherapy work better for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | March 5, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $630,650 |
| NIH project number | 5R01CA288526-02 |
| Project ID | NIH-11046677 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with solid tumors who are undergoing or considering immunotherapy.
✕Less likely to help
Patients with non-solid tumors or those not receiving immunotherapy may not benefit from this research.
What this research studies
This research focuses on understanding the role of a specific protein, MS4A7, found in tumor-associated macrophages (TAMs) and its impact on the effectiveness of immunotherapy in cancer treatment. By studying both human tumors and animal models, the researchers aim to uncover how MS4A7 contributes to immune resistance against cancer therapies. The project will explore the interactions between MS4A7 and other immune-related proteins, potentially identifying new targets for treatment that could enhance the efficacy of immunotherapy.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy strategies for cancer patients, enhancing their chances of effective treatment.
How similar studies have gone: Previous research has shown promising results in targeting immune resistance mechanisms in cancer, suggesting that this approach could lead to significant advancements.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Zou, Weiping — University of Michigan at Ann Arbor
- Study coordinator: Zou, Weiping
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.